Personalis to Announce Third Quarter 2025 Financial Results

FREMONT, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern … [Read more…]

ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis

A Global Turning Point for Critical Care Medicine TOULOUSE, France & FULLERTON, Calif.–(BUSINESS WIRE)–ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the world’s only recombinant apoA-I, today announced the publication of a ground breaking study in Scientific Reports in Nature Portfolio titled “Plasma apolipoprotein A-I is a … [Read more…]

Medifast to Announce Financial Results for the Third Quarter Ended September 30, 2025

BALTIMORE–(BUSINESS WIRE)–Medifast (NYSE: MED), the 40+ year old health and wellness company known for its science-backed, coach-guided lifestyle system, will announce financial results for the quarter ended September 30, 2025 on Monday, November 3, 2025, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company … [Read more…]

Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults

Findings presented at IDWeek 2025 underscore the importance of considering serotypes that disproportionately impact adults in the U.S. and show greater resistance to commonly prescribed antibiotics RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of findings from a systematic literature review of studies … [Read more…]

Late-breaking data from Phase III OCEANIC-STROKE study accepted for presentation at World Stroke Congress 2025

Bayer to unveil latest details on study design and baseline characteristics of the Phase III OCEANIC-STROKE study with asundexian Investigational agent asundexian is a once-daily, oral Factor XIa (FXIa) inhibitor WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer will present methods and baseline characteristic data from the global Phase III OCEANIC-STROKE study with the investigational agent asundexian, in a late-breaking … [Read more…]

Auna S.A. Announces Commencement of Cash Tender Offer and Consent Solicitation of Any and All of Its Outstanding 10.000% Senior Secured Notes Due 2029

(CUSIP NOS. 05151A AA1 / L0415A AA1) LUXEMBOURG–(BUSINESS WIRE)–Auna S.A. (NYSE: AUNA), a public limited liability company (société anonyme) incorporated and existing under the laws of Luxembourg, having its registered office at 6, rue Jean Monnet, L-2180 Luxembourg, and registered with the Luxembourg Trade and Companies Register (Registre de Commerce et des Sociétés, Luxembourg) under … [Read more…]

Samsung Bioepis And Phrontline Announce a Global Strategic Partnership to Advance Best-in-Class Antibody-Drug Conjugate Therapeutics for Solid Tumors

Samsung Bioepis and Phrontline will co-develop two investigational antibody-drug conjugate (ADC) assets directed against targets expressed in a broad range of cancers Collaboration will add a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis’ oncology portfolio Phrontline will be responsible for creating bispecific, dual-payload ADCs using its bispecific antibody and dual-linker payload … [Read more…]

Smarter Codes, Speedier Reimbursements: Suki Supercharges Revenue Cycle with Next-Gen AI

Introduces New Model That Delivers Greater Coding Precision and Automation to Reduce Errors, Accelerate Payments, and Close the Loop Between Care and Revenue REDWOOD CITY, Calif.–(BUSINESS WIRE)–Suki, the leader in artificial intelligence (AI) technology for healthcare, today announced its expansion of assisted revenue cycle capabilities powered by ambient clinical intelligence models that significantly improve a … [Read more…]

Meitheal Pharmaceuticals to Present New Data in Infectious Disease Portfolio at IDWeek 2025

New data examining fosfomycin for injection’s ability to treat acute pyelonephritis (AP) and complicated urinary tract infections (cUTIs) to be presented in three poster sessions Additional analyses from Phase 2/3 ZEUS clinical trial of fosfomycin for injection for cUTI to be shared Breadth of data presented demonstrates fosfomycin for injection’s effectiveness in combatting infections and … [Read more…]

Bayou Surgical Introduces Next-Generation 5 mm troCarWash™ System for Automated Laparoscope Cleaning

HOUSTON–(BUSINESS WIRE)–Bayou Surgical, innovators in intraoperative visualization, today announces the launch of its new 5mm troCarWash™ system — the newest and most advanced automated laparoscope cleaning solution designed to maintain clear vision during minimally invasive surgery (MIS) without removing the scope from the surgical field. The 5mm troCarWash™ builds on Bayou’s existing 10mm platform, incorporating … [Read more…]